Pharmacor says AstraZeneca’s Brilinta patent should not have been extended

Intellectual Property 2024-11-22 2:45 pm By Sam Matthews | Melbourne

As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.